Literature DB >> 28318761

The bone marrow microenvironment - Home of the leukemic blasts.

Manar S Shafat1, Bruno Gnaneswaran2, Kristian M Bowles3, Stuart A Rushworth4.   

Abstract

Acute Myeloid Leukaemia (AML) is a genetically, biologically and clinically heterogeneous set of diseases, which are characterised by an increased growth of abnormal myeloid progenitor cells within the bone marrow (BM). Ex-vivo AML exhibits a high level of spontaneous apoptosis. Furthermore, relapse for patients achieving remission occurs from minimal residual disease harboured within the BM microenvironment. Taken together, these observations illustrate the importance of the BM microenvironment in sustaining AML. While significant progress has been made elaborating the small-scale genetic mutations and larger-scale chromosomal translocations that contribute to the development of AML and its prognosis in response to treatment, less is understood about the complex microenvironment of the BM, which is known to be a key player in the pathogenesis of the disease. As we look towards future therapies, the consideration that the BM microenvironment is uniquely important as a niche for AML - coupled with the idea that leukaemic blasts are more likely to be genetically unstable and therefore evolve resistance to conventional chemotherapies - make the functions of the non-malignant cells of the BM attractive targets for therapy. In this review, we discuss the microanatomy of the BM and provide an overview of the evidence supporting the role of the BM microenvironment in creating conditions conducive to the survival and proliferation of AML blasts. Ultimately, we examine the therapeutic potential of uncoupling AML from the BM microenvironment.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukaemia; Bone marrow; Bone marrow microenvironment

Mesh:

Year:  2017        PMID: 28318761     DOI: 10.1016/j.blre.2017.03.004

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  46 in total

Review 1.  Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies.

Authors:  Luiza Handschuh
Journal:  J Oncol       Date:  2019-07-30       Impact factor: 4.375

Review 2.  Role of bone marrow adipocytes in leukemia and chemotherapy challenges.

Authors:  Azin Samimi; Majid Ghanavat; Saeid Shahrabi; Shirin Azizidoost; Najmaldin Saki
Journal:  Cell Mol Life Sci       Date:  2019-02-04       Impact factor: 9.261

Review 3.  CBP/Catenin antagonists: Targeting LSCs' Achilles heel.

Authors:  Yong-Mi Kim; Eun-Ji Gang; Michael Kahn
Journal:  Exp Hematol       Date:  2017-05-04       Impact factor: 3.084

4.  Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.

Authors:  Annachiara Dozzo; Aoife Galvin; Jae-Won Shin; Santo Scalia; Caitriona M O'Driscoll; Katie B Ryan
Journal:  Drug Deliv Transl Res       Date:  2022-08-05       Impact factor: 5.671

Review 5.  Dynamic responses of the haematopoietic stem cell niche to diverse stresses.

Authors:  Antoniana Batsivari; Myriam Luydmila Rachelle Haltalli; Diana Passaro; Constandina Pospori; Cristina Lo Celso; Dominique Bonnet
Journal:  Nat Cell Biol       Date:  2020-01-06       Impact factor: 28.824

6.  Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes.

Authors:  An Wu; Panpan Gao; Ningning Wu; Cong Shi; Zhenya Huang; Chunmeng Rong; Ye Sun; Lixia Sheng; Guifang Ouyang; Qitian Mu
Journal:  BMC Cancer       Date:  2021-05-13       Impact factor: 4.638

7.  Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia.

Authors:  Jayna J Mistry; Charlotte Hellmich; Amelia Lambert; Jamie A Moore; Aisha Jibril; Angela Collins; Kristian M Bowles; Stuart A Rushworth
Journal:  Biomark Res       Date:  2021-05-13

Review 8.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

Review 9.  Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.

Authors:  Natasha Mupeta Kaweme; Fuling Zhou
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

10.  Identification and validation of inferior prognostic genes associated with immune signatures and chemotherapy outcome in acute myeloid leukemia.

Authors:  Jie Wang; Jian-Ping Hao; Md Nazim Uddin; Yun Wu; Rong Chen; Dong-Feng Li; Dai-Qin Xiong; Nan Ding; Jian-Hua Yang; Xuan-Sheng Ding
Journal:  Aging (Albany NY)       Date:  2021-06-18       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.